The INDIGO trial: Precision medicine finally comes to glioma
Neuro Oncol
.
2023 Nov 2;25(11):1918-1919.
doi: 10.1093/neuonc/noad162.
Authors
Diana D Shi
1
,
William G Kaelin
2
3
Affiliations
1
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
3
Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
PMID:
37698505
PMCID:
PMC10628926
(available on
2024-10-12
)
DOI:
10.1093/neuonc/noad162
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Glioma*
Humans
Indigo Carmine
Indigofera*
Indoles
Precision Medicine
Substances
Indigo Carmine
Indoles
Grants and funding
K12 CA090354/CA/NCI NIH HHS/United States
R35 CA210068/CA/NCI NIH HHS/United States
5R35CA210068-02/GF/NIH HHS/United States
HHMI/Howard Hughes Medical Institute/United States